EXTENDED REPORTS

Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response

T Jónsdóttir, I Gunnarsson, A Risselada, E W Henriksson, L Klareskog, R F van Vollenhoven

¹ Department of Rheumatology, Karolinska University Hospital, Stockholm, Sweden

Dr Ronald F van Vollenhoven, Department of Rheumatology, D2:01, Karolinska University Hospital, Solna, S-171 76 Stockholm, Sweden; ronald.van.vollenhoven{at}ki.se

Objective: To evaluate efficacy, serological responses, and predictors of response in patients with severe and refractory systemic lupus erythematosus (SLE) treated with rituximab plus cyclophosphamide.

Methods: 16 patients entered a treatment protocol using rituximab plus cyclophosphamide. Disease activity was assessed by the SLE disease activity index (SLEDAI) and by the British Isles Lupus Assessment Group (BILAG) index.

Results: At six months follow up, mean SLEDAI values decreased significantly from (mean (SD)) 12.1 (2.2) to 4.7 (1.1). Clinical improvement (50% reduction in SLEDAI) occurred in all but three patients. All but one patient responded according to BILAG. Remission defined as SLEDAI <3 was achieved in nine of 16 patients. Isotype analysis of anti-dsDNA antibodies revealed preferential decreases of IgG and IgA, but not IgM. Higher absolute numbers of CD19+ cells at baseline were correlated with shorter depletion time (r = –0.6).

Conclusions: The majority of patients improved following rituximab plus cyclophosphamide. The differential downregulation of anti-DNA of the IgG and IgA but not the IgM isotypes supports the hypothesis that cells producing pathogenic autoantibodies are preferentially targeted by the treatment. The fact that greater absolute numbers of CD19+ cells at baseline predict a less impressive clinical and serological response suggests that more flexible dosing could be advantageous.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Ramos-Casals, M, Soto, M., Cuadrado, M., Khamashta, M. (2009). Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 cases. Lupus 18: 767-776 [Abstract]  
• Zheng, W J, Zhang, X, Wang, Q, Xu, D, Zeng, X F, Zhang, F C (2009). Refractory severe connective tissue disease thrombocytopenia: is rituximab treatment effective and safe?. Ann Rheum Dis 68: 1077-1078 [Full Text]  
• Karim, M. Y., Pisoni, C. N., Khamashta, M. A. (2009). Update on immunotherapy for systemic lupus erythematosus--what's hot and what's not!. Rheumatology (Oxford) 48: 332-341 [Abstract] [Full Text]  
• Kumar, S., Benseler, S. M., Kirby-Allen, M., Silverman, E. D. (2009). B-Cell Depletion for Autoimmune Thrombocytopenia and Autoimmune Hemolytic Anemia in Pediatric Systemic Lupus Erythematosus. Pediatrics 123: e159-e163 [Abstract] [Full Text]  
• Lu, T Y-T, Jonsdottir, T, van Vollenhoven, R F, Isenberg, D A (2008). Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two cases. Ann Rheum Dis 67: 1493-1494 [Full Text]  
• Isenberg, D. (2008). Treating patients with lupus with B-cell depletion. Lupus 17: 400-404 [Abstract]